Hematology

In instances when longer term or repeat treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of treatment and at least annually thereafter. If clinical effectiveness has not been achieved, IG should be discontinued.

Hemolytic disease of the fetus (HDF), prevention (i.e., maternal)

Recommended Indications in which IG can be used:
Order Number: H4-HDF

Hemolytic Disease of the Fetus and Newborn (HDFN)

Recommended Indications in which IG can be used:
Order Number: H5-HDN

Hemolytic transfusion reaction (HTR)

Not for Routine Use:
Order Number: H21-HTR

Hemolytic transfusion reaction in sickle cell disease (HTRSCD)

Not for Routine Use:
Order Number: H19-HTRSCD

Hemolytic uremic syndrome

Do Not Use

Hemophagocytic lympohistiocytosis (HLH) syndrome – Primary HLH

Do Not Use

Heparin-induced thrombocytopenia (HIT)

Recommended Indications in which IG can be used:
Order Number: H6-HIT

Hypogammaglobulinemia acquired secondary to hematological malignancies

Recommended Indications in which IG can be used:
Order Number: I2-SID

Immune thrombocytopenia (ITP) Adult

Recommended Indications in which IG can be used:
Order Number: H8-ITPA

Immune Thrombocytopenia (ITP) Pediatric

Recommended Indications in which IG can be used:
Order Number: H10-NHP